A Review of Preclinical Evidence and Translational Gaps

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia arising from impaired insulin secretion, insulin action, or both. Plant-derived products are investigated as possible sources of complementary antidiabetic agents because they contain chemically diverse constituents that may influence glucose regulation and diabetes-associated tissue injury. This review critically summarizes the preclinical evidence supplied for Azadirachta indica (neem) and Garcinia indica (kokum), with emphasis on glycaemic control, insulin-related pathways, oxidative stress, lipid abnormalities and organ-protective outcomes. Neem studies in chemically induced and diet-associated diabetic rodents report reductions in blood glucose, improvements in lipid indices, restoration of antioxidant enzymes and changes in insulin-signalling proteins. However, one neonatal streptozotocin model found that a 0.8% neem leaf preparation improved beta-cell morphology but did not restore glucose homeostasis, illustrating that outcomes depend on the model and preparation. Kokum studies report that aqueous fruit extract lowered fasting and postprandial glucose and restored erythrocyte glutathione in diabetic rats; other studies found glucose-, lipid- and renal-profile improvements with fruit-rind extracts, while a seed methanolic extract also reduced glucose in streptozotocin-treated rats. These findings are promising but remain preclinical. Differences in plant part, extraction solvent, dose, duration and diabetes model limit direct comparison. The evidence base lacks adequate standardization, pharmacokinetic characterization, long-term toxicology and controlled human efficacy data. Neither plant should be considered a proven substitute for established diabetes treatment. Further work should prioritize authenticated and chemically standardized extracts, reproducible dose-response studies, mechanistic validation, safety assessment and carefully designed clinical trials

Authors

Publication Details

Journal
International Journal of Advanced Research in Science Communication and Technology
Published
2026-11-03
DOI
https://doi.org/10.48175/ijarsct-40542
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Review of Preclinical Evidence and Translational Gaps

Miss. Gunjal Priyanka B and Mr. Bhane Aniket R, Mrs. Puja Khemnar K
International Journal of Advanced Research in Science Communication and Technology
Natural Antidiabetic Agents Studies
article

A Review of Preclinical Evidence and Translational Gaps

Miss. Gunjal Priyanka B and Mr. Bhane Aniket R, Mrs. Puja Khemnar K
article en

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia arising from impaired insulin secretion, insulin action, or both. Plant-derived products are investigated as possible sources of complementary antidiabetic agents because they contain chemically diverse constituents that may influence glucose regulation and diabetes-associated tissue injury. This review critically summarizes the preclinical evidence supplied for Azadirachta indica (neem) and Garcinia indica (kokum), with emphasis on glycaemic control, insulin-related pathways, oxidative stress, lipid abnormalities and organ-protective outcomes. Neem studies in chemically induced and diet-associated diabetic rodents report reductions in blood glucose, improvements in lipid indices, restoration of antioxidant enzymes and changes in insulin-signalling proteins. However, one neonatal streptozotocin model found that a 0.8% neem leaf preparation improved beta-cell morphology but did not restore glucose homeostasis, illustrating that outcomes depend on the model and preparation. Kokum studies report that aqueous fruit extract lowered fasting and postprandial glucose and restored erythrocyte glutathione in diabetic rats; other studies found glucose-, lipid- and renal-profile improvements with fruit-rind extracts, while a seed methanolic extract also reduced glucose in streptozotocin-treated rats. These findings are promising but remain preclinical. Differences in plant part, extraction solvent, dose, duration and diabetes model limit direct comparison. The evidence base lacks adequate standardization, pharmacokinetic characterization, long-term toxicology and controlled human efficacy data. Neither plant should be considered a proven substitute for established diabetes treatment. Further work should prioritize authenticated and chemically standardized extracts, reproducible dose-response studies, mechanistic validation, safety assessment and carefully designed clinical trials

International Journal of Advanced Research in Science Communication and Technology
Openalex Percentile: Top 12%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
A Review of Preclinical Evidence and Translational Gaps — Miss. Gunjal Priyanka B and Mr. Bhane Aniket R, Mrs. Puja Khemnar K · International Journal of Advanced Research in Science Communication and Technology (2026) | TGRS Research Map | TGRS